Medtronic and MercadoLibre remain top buy-and-hold candidates as both companies navigate strategic growth initiatives and market headwinds to secure future dominance.
MercadoLibre is currently sacrificing short-term profitability to capture long-term market share through aggressive investments in free shipping and fintech expansion. Despite a drop in EPS to $9.19 in the second quarter, the company's 50% revenue growth and its ability to leverage network effects in underbanked Latin American markets suggest a strong competitive moat. The stock's 18% decline over the past year presents a potential entry point for investors betting on the region's e-commerce and digital finance growth.
The EPS decline was primarily due to increased investments in free shipping and higher credit loss provisions associated with expanding its fintech and credit card offerings.
The thesis relies on the company's ability to strengthen its competitive moat through network effects, high switching costs, and capturing the growth of the underbanked population in Latin America.
Despite lagging broader market gains, Medtronic and MercadoLibre present compelling long-term opportunities. Medtronic continues to deliver strong revenue growth and dividend consistency, while MercadoLibre leverages aggressive ecosystem investments to capture the underbanked Latin American market.
The company is aggressively investing in free shipping and fintech credit offerings, which has temporarily compressed net income and margins.
Medtronic is currently driven by its cardiac ablation solutions, the upcoming rollout of the Hugo robotic-assisted surgery system, and planned margin improvements.